GENELUX Corp
About GENELUX Corp
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $8.0K
- Net income
- -$32.1M
- Total assets
- $19.0M
- Market cap
- $131.4M
- Operating margin
- -415175.0%
- Net margin
- -401812.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $8.0K
- Operating expenses
- $33.2M
- Operating income
- -$33.2M
- Net income
- -$32.1M
- EPS (basic)
- $-0.86
- EPS (diluted)
- $-0.86
Balance sheet
- Total assets
- $19.0M
- Current assets
- $15.1M
- Total liabilities
- $7.5M
- Current liabilities
- $6.2M
- Shareholders’ equity
- $11.5M
Cash flow
- Operating cash flow
- -$25.3M
- Investing cash flow
- $12.1M
- Financing cash flow
- $9.9M
- Net cash flow
- -$3.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $131.4M
- EPS (diluted)
- $-0.86
- Shares outstanding
- 44.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 26, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $32.1M in FY2025.
- Revenue declined 95% from FY2023 to FY2025.
- Trading 64% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GENELUX Corp.
Write a review
News about GENELUX Corp
News & sentiment via Polygon.io
